Steroids In caRdiac Surgery Trial (SIRS Trial)

Cardiopulmonary Bypass Clinical Trial

Official title:

Phase IV Study of Perioperative Steroid's Effects on Death or MI in High-Risk Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00427388
• Other study ID #: SIRS 2007
• Status: Active, not recruiting
• Phase: Phase 4
• First received: January 26, 2007
• Last updated: July 31, 2014
• Start date: June 2007
• Est. completion date: August 2014

Study information

• Verified date: July 2014
• Source: McMaster University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Canadian Institutes of Health ResearchCanada: Health Canada
• Study type: Interventional

Clinical Trial Summary

SIRS trial is a large simple study in which high-risk patients undergoing cardiac surgery requiring the use of cardiopulmonary bypass (CPB) are randomly allocated to receive a pulse dose of Methylprednisolone or a matching placebo. Cardiopulmonary bypass initiates a systemic inflammatory response that facilitates development of post-operative complications. SIRS will confirm or deny the potential clinical benefits of suppressing this response through the use of systemic steroids. Specifically, does 250 mg of intravenous Methylprednisolone given twice, once on anesthetic induction and again on CPB initiation, result in improved early survival and less myocardial infarction in high-risk cardiac surgery patients requiring CPB?

Description:

Cardiopulmonary bypass (CPB) is a commonly performed surgical procedure with over 500,000 per year in North America. CPB initiates a systemic inflammatory response characterized by both cell and protein activation. Platelets, neutrophils, monocytes, macrophages, coagulation, fibrinolytic, and kallikrein cascades all take part in what results in increased endothelial permeability, vascular, and parenchymal damage. These inflammatory pathways facilitate development of post-operative complications including thrombosis, myocardial injury and infarction, respiratory failure, renal and neurological dysfunction, bleeding disorders, altered liver function and ultimately, multiple organ failure.

In an attempt to minimize the deleterious effects of CPB, investigators have tested a variety of strategies in cardiac surgery ranging from the complete avoidance of CPB, to the use of biocompatible circuits and pharmacologic agents to abrogate the systemic response. Investigators have consistently demonstrated the efficacy of steroids as the most potent anti-inflammatory agent for use during CPB. In fact, from the available evidence, the 2004 AHA guidelines for coronary artery bypass grafting (CABG) "support liberal prophylactic use in patients undergoing extracorporeal circulation". However, the trials that do exist within this literature are focused on biochemical endpoints and are insufficiently powered to make conclusions on hard clinical endpoints. Our pilot RCT, SIRS I, demonstrated the efficacy of a low dose steroid protocol in the suppression of this inflammatory cascade. We hypothesize that this low dose protocol will yield clinical benefit while avoiding the potential adverse effects of steroids which are known to be dose dependent.

The primary aim of the SIRS trial is to determine if perioperative pulse dose Methylprednisolone results in improved early survival and less myocardial infarction in cardiac surgery requiring CPB. Additional secondary aims of the SIRS trial are to determine the effect of steroids on other clinical outcomes including length of stay, new onset atrial fibrillation, transfusion requirements, infectious, wound, and gastrointestinal complications.

The design of the SIRS trial is a prospective multicentre international double-blind placebo controlled randomized clinical trial. The sample size of 7500 patients will have 80% to 90% power to detect a 20-30% RRR for the primary outcome with an α=0.05 (two-sided), anticipating a 6% rate of death in the control arm. Our aim is to have 85 international centers participate which, recruiting at 5 patients per month, would complete recruitment in 36 months. This will be a large trial with a simple design and objective outcomes.

A sub-group of patients will be enrolled in a renal sub-study. This sub-study will determine if the risk of acute kidney injury is lower in patients treated with intravenous steroid versus placebo, if steroids lead to better preservation of kidney function six months after cardiac surgery, and whether the impact of steroid exposure differs in patients with and without pre-operative chronic kidney disease.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 7507
• Est. completion date: August 2014
• Est. primary completion date: February 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age greater than 18 years

2. Require CPB for any cardiac surgical procedure (such as CABG, Valve, Aorta, or combined procedures)

3. Must have a EuroSCORE = 6

4. Provide written informed consent

NOTE: For participating sites in India, China and Hong Kong, the following eligibility criteria will be applied:

1. Age greater than 18 years

2. Require CPB for any cardiac surgical procedure (such as CABG, Valve, Aorta, or combined procedures)

3. Must have at least one of the following:

1. EuroSCORE greater than or equal to 4 and undergoing valvular surgery

2. EuroSCORE greater than or equal to 6 and undergoing any other cardiac surgery procedure (i.e. CABG, Aorta)

4. Provide written informed consent

Exclusion Criteria:

1. Use of systemic corticosteroids

2. History of bacterial or fungal infection in last 30 days

3. Allergy/intolerance to corticosteroids

4. Will receive Aprotinin

5. Previous participation in study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cardiac Surgical Procedures
• Cardiopulmonary Bypass
• Systemic Inflammatory Response Syndrome

Intervention

Drug:
• Methylprednisolone
Given by IV in 2 doses (250 mg each dose for a total of 500 mg)

Other:
• Placebo
Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)

Locations

Country	Name	City	State
Canada	Hamilton General Hospital	Hamilton	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Population Health Research Institute	Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

References & Publications (4)

Garg AX, Vincent J, Cuerden M, Parikh C, Devereaux PJ, Teoh K, Yusuf S, Hildebrand A, Lamy A, Zuo Y, Sessler DI, Shah P, Abbasi SH, Quantz M, Yared JP, Noiseux N, Tagarakis G, Rochon A, Pogue J, Walsh M, Chan MT, Lamontagne F, Salehiomran A, Whitlock R; SIRS Investigators. Steroids In caRdiac Surgery (SIRS) trial: acute kidney injury substudy protocol of an international randomised controlled trial. BMJ Open. 2014 Mar 5;4(3):e004842. doi: 10.1136/bmjopen-2014-004842. — View Citation

Whitlock R, Teoh K, Vincent J, Devereaux PJ, Lamy A, Paparella D, Zuo Y, Sessler DI, Shah P, Villar JC, Karthikeyan G, Urrútia G, Alvezum A, Zhang X, Abbasi SH, Zheng H, Quantz M, Yared JP, Yu H, Noiseux N, Yusuf S. Rationale and design of the steroids in cardiac surgery trial. Am Heart J. 2014 May;167(5):660-5. doi: 10.1016/j.ahj.2014.01.018. Epub 2014 Mar 1. — View Citation

Whitlock RP, Rubens FD, Young E, Teoh KH. Pro: Steroids should be used for cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2005 Apr;19(2):250-4. Review. — View Citation

Whitlock RP, Young E, Noora J, Farrokhyar F, Blackall M, Teoh KH. Pulse low dose steroids attenuate post-cardiopulmonary bypass SIRS; SIRS I. J Surg Res. 2006 May 15;132(2):188-94. Epub 2006 Mar 29. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality at 30 days		30 days post-randomization	No
Primary	Composite	Incidence of the composite outcome of death, myocardial infarction, stroke, renal failure (KDIGO Stage III acute kidney injury, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines), or respiratory failure within 30 days	30 days post-randomization	No
Secondary	MI or Mortality at 30 days	Composite of death or significant myocardial infarction within 30 days post-randomization	30 days post-randomization	No
Secondary	Mortality at 6 months	All-cause mortality at 6 months post-randomization	6 months post-randomization	No
Secondary	Atrial Fibrillation	New onset atrial fibrillation within 30 days post-randomization	30 days post-randomization	No
Secondary	Transfusion Requirements	Transfusion requirements within first 24 hours post-operative	24 hours post-surgery	No
Secondary	Chest Tube Output	Chest tube output within first 24 hours post-operative	24 hours post-surgery	No
Secondary	ICU and Hospital Length of Stay	Length of ICU stay and hospital stay	Hospital Discharge	No
Secondary	Infection	Infection within 30 days post-randomization	30 days post-randomization	Yes
Secondary	Delirium	Delirium at day 3 post-operative	3 days post-surgery	Yes
Secondary	Wound Complication	Wound complication within 30 days post-randomization	30 days post-randomization	Yes
Secondary	GI Hemorrhage	GI hemorrhage or GI perforation within 30 days post-randomization	30 days post-randomization	Yes
Secondary	Insulin Use	Post-operative insulin use within the first 24 hours after surgery	24 hours post-surgery	Yes
Secondary	Peak Blood Glucose	Peak blood glucose within the first 24 hours after surgery	24 hours post-surgery	Yes